EU Pharma Package – Bolar exemption under scrutiny and first amendments being proposed - Kluwer Patent Blog: The European Commission (EC) has proposed a Pharmaceutical Directive to increase competition… https://t.co/tM4Vn1Pvsc - IP topics #ip#intellectualproperty#copyright
We're excited to have Jiri Slavik, Sr Manager IP from Adalvo join our #LSPNEurope speaker line-up. Join us on November 29, 2022 in London and find out about supplementary protection certificates - applications, requirements & range of use. Register now: https://t.co/LVrgpVUIvE
👩🏻💻 CEIPI is welcoming today, on the occasion of its 33rd European tutors' meeting on 12 and 13 May, around 60 specialists in European Patent law, coming from several European countries 🇪🇺, as well as representatives of the European Patent Academy and the WIPO.
📣 European Qualifying Examination (EQE) 2023 - start planning your preparation now with CEIPI!
ℹ️ For more details and access to the application forms, please visit the dedicated page of the #CEIPI website: https://t.co/6mVUR5bFTo
#EQE
cc: @DebledThierry
Last week CEIPI had the pleasure of welcoming speakers and participants of the Advanced Training Program on Regulatory Affairs and Intellectual Property Protection in the Pharmaceutical Industry.
More info about the seminar: https://t.co/EakLp43HYD
The 19th edition of the Diploma "Patent Litigation in Europe" kicked off this morning.
The programme, under the Direction of Emmanuel Gougé and @FranckMacrez, is designed to train senior patent professionals wishing to deepen their expertise in #patentlaw in #Europe.
Další zrušující rozhodnutí NSS. Testování v malých firmách,zavření středních škol.
Rozsudek o školách stojí za přečtení pro druh inteligentního humoru👇, který je fanatikům obou stran patrně nepřístupný. Ale snad ho ocení studenti těch středních škol. Vřele doporučuji @obcankari
I've just registered for LSPN connect for an event "Justice Colin Birss Interview". Use this link to use my friends' and colleagues' discount! #LSPNConnect@LifeSciencesIPR https://t.co/MTZPZ0z2vl